Davies, Andrew; Cummin, Thomas E; Barrans, Sharon; Maishman, Tom; Mamot, Christoph; Novak, Urban; Caddy, Josh; Stanton, Louise; Kazmi-Stokes, Shamim; McMillan, Andrew; Fields, Paul; Pocock, Christopher; Collins, Graham P; Stephens, Richard; Cucco, Francesco; Clipson, Alexandra; Sha, Chulin; Tooze, Reuben; Care, Matthew A; Griffiths, Gareth; ... (2019). Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. The lancet oncology, 20(5), pp. 649-662. Elsevier 10.1016/S1470-2045(18)30935-5
|
Text
showPdf.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (463kB) | Preview |
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Novak, Urban |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1474-5488 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Rebeka Gerber |
Date Deposited: |
21 Jun 2019 15:50 |
Last Modified: |
05 Dec 2022 15:28 |
Publisher DOI: |
10.1016/S1470-2045(18)30935-5 |
PubMed ID: |
30948276 |
BORIS DOI: |
10.7892/boris.129931 |
URI: |
https://boris.unibe.ch/id/eprint/129931 |
Actions (login required)
 |
Edit item |